Yan J, Xie W, Lin YH, Feng X, Wang BB, Xiao J, Ou WN, Wang YB, Cheng J. Effect of adeforvir dipivoxil on the frequency of HBcAg-specific cytotoxic T cells in patients with chronic hepatitis B.
Shijie Huaren Xiaohua Zazhi 2009;
17:1996-1999. [DOI:
10.11569/wcjd.v17.i19.1996]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of adeforvir dipivoxil on HBcAg-specific cytotoxic T cells in patients with chronic hepatitis B(CHB).
METHODS: The frequency of circulating HBcAg-specific cytotoxic T cells in 11 HLA-A2+ chronic hepatitis B patients were studied longitudinally before and after adeforvir dipivoxil therapy by HLA-A2/peptide tetramer staining.
RESULTS: The frequency of HBcAg-specific cytotoxic T cells ranged from 0.074% to 0.937%. The frequency of HBcAg-specific cytotoxic T cells in chronic hepatitis B patients was lower than that in acute hepatitis B patients. No significant difference was observed in the frequency of HBcAg-specific cytotoxic T cells between before and after adeforvir dipivoxil therapy. Subgroup analysis indicated that, after therapy with adeforvir dipivoxil for 48 hours, HBV DNA or ALT levels had no effect on the frequency of HBcAg-specific cytotoxic T cells.
CONCLUSION: Adeforvir dipivoxil probably exerts no effect on the frequency of HBcAg-specific cytotoxic T cells in patients with CHB.
Collapse